Clinical trials: Carcinoma in Situ
Ductal Carcinoma in Situ, Breast Cancer
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
This study will investigate a novel approach to marking surgical cavity margins following tumor resection, to allow for more accurate radiotherapy following oncoplastic surgery.
- Trial name
- NCT06903468
- Testing
- Novel cavity marking technique
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Nevus, Dysplasia; Epithelial
Skin Fluorescent Imaging (SFI) System in Patients With Nevi
The Sponsor has developed the Skin Fluorescent Imaging (SFI) system, an in vivo imaging modality, for the purpose of providing physicians with insight into the biological changes occurring during tissue remodeling in a nevus.
- Trial name
- NCT04368247
- Testing
- Skin Fluorescent Imaging
- Where
- 4 sites in United States
- Volunteers
- 300 people
- Sponsor
- Orlucent, Inc
Atrophic Gastritis With Low-grade Intraepithelial Neoplasia
Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial
Fuzheng Nizeng Formula (FZNZ) is derived from the classic formula Liujunzi Decoction. Former pilot study found that FZNZ promoted the recovery of gastric atrophy and relieve the relative symptoms.
- Trial name
- NCT06324825
- Testing
- Fuzhegn Nizeng Decoction, Moluodan granules
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Peking University First Hospital
Ductal Carcinoma in Situ
Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates
This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to…
- Trial name
- NCT05961280
- Testing
- Mastectomy with sentinel lymph node biopsy
- Volunteers
- 385 people
- Sponsor
- Gangnam Severance Hospital
Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or…
- Conditions
- Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
- Trial name
- NCT06833073
- Testing
- Intismeran autogene, BCG
- Where
- 89 sites in United States, Argentina and 17 more
- Volunteers
- 308 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Muscle Invasive Bladder Cancer
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
Standard treatment for patients with high-risk NMIBC (high-grade Ta, CIS, or any T1) consists of intravesical Bacillus Calmette-Guerin (BCG) immunotherapy.
- Trial name
- BRACE (NCT06990061)
- Testing
- Radiation therapy
- Where
- 3 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Fibrosis, Breast Cancer
An Integrated Optimization of Surgery and Radiotherapy Techniques to Improve Cosmetic Outcome and Quality of Life in Breast Conserving Therapy for Breast Cancer Patients (STARLINGS Study)
To assess the role of different combinations of (oncoplastic) surgery and radiotherapy techniques as risk factors for moderate to severe fibrosis and for moderate to poor cosmetic outcome.
- Conditions
- Breast Fibrosis, Breast Cancer, Breast Cancer Female, Breast Neoplasms
- Trial name
- STARLINGS (NCT05263362)
- Testing
- no intervention
- Where
- 4 sites in Netherlands
- Volunteers
- 775 people
- Sponsor
- Erasmus Medical Center
Bladder Carcinoma in Situ (CIS)
Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
Phase I exploratory, open-label, single arm, multicenter study to assess safety, tolerability and antitumor activity of ONCOFID-P-B™ therapy in adult patients with histologically confirmed diagnosis of bladder carcinoma in situ…
- Trial name
- NCT04798703
- Testing
- ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
- Where
- 5 sites in Italy, Spain
- Volunteers
- 20 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Breast Cancer
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ.
- Trial name
- NCT00082667
- Testing
- gefitinib, Surgery
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Gastric Dysplasia, Gastric Cancer in Situ
Endoscopic Closure of Gastric ESD Defect
This is a pilot study to investigate the usefulness of closure of mucosal defect after gastric endoscopic submucosal dissection (ESD) in patients that are at high risk of post-procedural haemorrhage.
- Trial name
- NCT04282707
- Testing
- Endoscopic closure of ESD defect, Gastric ESD without closure of ESD defect
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Adenocarcinoma of the Lung, Large Cell Lung Cancer
Photodynamic Therapy in Treating Patients With Lung Cancer
This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT01668823
- Testing
- HPPH, photodynamic therapy, therapeutic bronchoscopy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Hot Flashes
Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer
RATIONALE: Venlafaxine may be effective in relieving hot flashes caused by hormone therapy. Giving venlafaxine with zolpidem (a sleeping pill) may improve sleep and quality of life in women who are receiving hormone therapy for…
- Conditions
- Breast Cancer, Hot Flashes, Sleep Disorders
- Trial name
- NCT00084669
- Testing
- venlafaxine, zolpidem tartrate, management of therapy complications
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer
To assess the role of interstitial brachytherapy alone compared to whole breast irradiation in a defined low-risk group of invasive breast cancer or ductal carcinoma in situ concerning local failure (all ipsilateral local…
- Trial name
- NCT00402519
- Testing
- Accelerated partial breast irradiation, External beam whole breast irradiation
- Where
- 11 sites in Austria, Germany and 3 more
- Volunteers
- 1,300 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Intraductal Carcinoma and Lobular Carcinoma in Situ
Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast
When invasive components are discovered at mastectomy for vacuum-assisted biopsy (VAB)-diagnosed ductal carcinoma in situ (DCIS), the only option available is axillary lymph node dissection (ALND).
- Trial name
- CINNAMOME (NCT01841749)
- Testing
- sentinel node biopsy and mastectomy
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Institut Bergonié
Breast Cancer
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy after surgery is effective in preventing a recurrence of ductal carcinoma in situ.
- Trial name
- NCT00077168
- Testing
- anastrozole, tamoxifen citrate, adjuvant therapy
- Where
- 29 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Fast Spectral Imaging Device for Tumor Margin Mapping
The objective of the proposed research is to develop a clinical-trial-ready device and to evaluate its practical utility as a routinely used intra-operative tool.
- Trial name
- NCT01107080
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Duke University
Oral Cancer
Erlotinib Prevention of Oral Cancer (EPOC)
The goal of this clinical research study is to learn if erlotinib hydrochloride (Tarcevaâ (OSI-774 ) can prevent cancer in the mouth of people with a high risk of developing cancer in the mouth.
- Trial name
- NCT00402779
- Testing
- Erlotinib
- Where
- 4 sites in United States
- Volunteers
- 303 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms
Intra-operative Radiotherapy For Breast Cancer Women After NSM
The role of NSM is still controversial, mainly because of concern about the oncologic safety of the nipple-areola complex (NAC).INTRABEAM (Carl Zeiss, Oberkochen, Germany) is the most widely used mobile intraoperative…
- Trial name
- NCT02389686
- Testing
- INTRABEAM (Carl Zeiss, Oberkochen, Germany)
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Liao Ning
Urinary Bladder Neoplasms, Carcinoma in Situ
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC).
- Conditions
- Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer
- Trial name
- NCT05014139
- Testing
- Enfortumab vedotin
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 37 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Bladder Cancer
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy.
- Trial name
- VISTA (NCT02449239)
- Testing
- Vicinium
- Where
- 70 sites in United States, Canada
- Volunteers
- 133 people
- Sponsor
- Sesen Bio, Inc.